10 Percent Neutral Buffered Formalin by Richard-Allan Scientific: Class I Recall - May Contain Incorrect Concentration of Formalin
Use of this defective Formalin may prevent or delay diagnoses and treatment decisions.
Italiano
Use of this defective Formalin may prevent or delay diagnoses and treatment decisions.
Risk of impaired ability to fight infections, high blood sugar levels, muscle injuries and psychiatric problems. Undeclared drug ingredients may also cause serious side effects when combined with other medications.
When a medicine is marketed, much is known about its quality and pharmacology and in its efficacy in a carefully screened group of patients in clinical trials. These data, however, may provide an incomplete and even misleading account of the drug’s effectiveness in the community at large. Even less is known at the time of marketing approval about its safety in the general population, because of the size of the clinical trials and the selected nature of the subjects included. In other words, its overall benefit-risk balance is uncertain.
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti
informazioni riguardo errori durante l’uso di OLIMEL.
L'Agenzia Italiana del Farmaco rende disponibili nuovi e importanti
aggiornamenti sulla carenza temporanea del medicinale Xofigo®.
Those with weakened immune system or chronic lung disease may be more susceptible to infections with B. cepacia.
L'Agenzia Italiana del Farmaco rende disponibili dei chiarimenti riguardo la Nota Informativa Importante su Konakion del 26/06/2014.
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti
informazioni di sicurezza sul medicinale Broncovaleas (salbutamolo), soluzione da nebulizzare e rischio di esposizione accidentale.
Intravenous administration of a solution containing sterile particulate matter may lead to adverse health consequences. Posted 10/25/2014
L’Agenzia Europea dei Medicinali ha completato una revisione dei medicinali contenenti polimixine.
80.211.154.110